Challenges in the development of magnetic particles for therapeutic applications.
Certain iron-based particle formulations have useful magnetic properties that, when combined with low toxicity and desirable pharmacokinetics, encourage their development for therapeutic applications. This mini-review begins with background information on magnetic particle use as MRI contrast agents and the influence of material size on pharmacokinetics and tissue penetration. Therapeutic investigations, including (1) the loading of bioactive materials, (2) the use of stationary, high-gradient (HG) magnetic fields to concentrate magnetic particles in tissues or to separate material bound to the particles from the body, and (3) the application of high power alternating magnetic fields (AMF) to generate heat in magnetic particles for hyperthermic therapeutic applications are then surveyed. Attention is directed mainly to cancer treatment, as selective distribution to tumors is well-suited to particulate approaches and has been a focus of most development efforts. While magnetic particles have been explored for several decades, their use in therapeutic products remains minimal; a discussion of future directions and potential ways to better leverage magnetic properties and to integrate their use into therapeutic regimens is discussed.
Barry
Stephen E
SE
Alnis BioSciences, Inc., Research Triangle Park, NC 27709, USA. sbarry@oncologic.net
D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D004574:Electromagnetic Fields; D005290:Ferric Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D006358:Hot Temperature; D006801:Humans; D008279:Magnetic Resonance Imaging; D008280:Magnetics; D053758:Nanoparticles; D009369:Neoplasms / Q000628:therapy; D010316:Particle Size
D003287:Contrast Media; D005290:Ferric Compounds; C000499:ferric oxide